ondasdechoque.org
PT-BR

Quadratus lumborum pain: waves or injection? · Comparison study · 2017

How does shockwave compare with injections for lower-back muscle pain?

In this study, people who chose shockwave for long-lasting lower-back muscle pain went from about 7 to about 2 out of 10 a month after three sessions. Those who chose trigger-point injections went from about 7 to about 4. Day-to-day function improved in both groups, without a clear difference.

Pain fell more than with injections
inpatients with lower-back muscle pain
30
sessions, three days apart
3
month of follow-up
1

Good to know: People chose their own treatment.

Hong JO, Park JS, Jeon DG, et al. Ann Rehabil Med, 2017 · Read the paper ↗

How this study worked

Shockwave15 peopleTrigger-pointinjections15 people
Groups were compared, but people were not assigned to them by lot. Each dot is one person.

What happened

Lower-back muscle pain

0–10 pain scale · start, after the third session and 1 month later

ShockwaveTrigger-point injections

By one month, pain had fallen from about 7 to about 2 out of 10 with shockwave and from about 7 to about 4 with injections.
Show the numbers
GroupStartAfter 3 sessions1 month later
Shockwave7.332.532.13
Trigger-point injections6.643.713.86

The treatment

Shockwave

Shockwave, every 3 days, 3 times

ShockwavesThe paper doesn’t say whether radial or focused
Sessions
3, every 3 days
Pulses
2,000 per session · aimed at the tender muscle with ultrasound
Strength
0.085–0.148mJ/mm²
Numbing
Not mentioned
Device
Dornier AR2
Everyone also got
Pain medicines, rest and therapeutic exercise

Compared with: Ultrasound-guided trigger-point injections, three times, three days apart, with the same medicines, rest and exercise

Settings are what each study used, not a prescription.

Who took part

30 hospital inpatients (17 men, 13 women; average age 53–55) with pain in a deep lower-back muscle (quadratus lumborum) for over three months.

Shockwave15 people
Trigger-point injections15 people

Side effects

No serious side effects, such as unbearable pain or skin infection, in either group during the month of follow-up.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Patients hospitalized April 2015–June 2016 with isolated QL myofascial pain lasting over three months. Imaging/electrodiagnosis excluded other spinal causes. Mean ages 55.46 and 53.13 years; 17 men/13 women overall.

ESWT15enrolled

Source reports this participant group.

Trigger-point injection15enrolled

Source reports this participant group.

Pain intensity2 reported outcomes
01
Immediately after third treatment

Pain intensity

VAS points

BaselineFollow-up
ESWT
2.53
Trigger-point injection
3.71
010 points
means
GroupnBaselineFollow-up
ESWT157.33 (SD 0.82)2.53 (SD 1.06)
Trigger-point injection156.64 (SD 1.08)3.71 (SD 0.73)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

02
One month after treatment

Pain intensity

VAS points

BaselineFollow-up
ESWT
2.13
Trigger-point injection
3.86
010 points
means
GroupnBaselineFollow-up
ESWT157.33 (SD 0.82)2.13 (SD 0.92)
Trigger-point injection156.64 (SD 1.08)3.86 (SD 0.95)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Algometry2 reported outcomes
03
Immediately after third treatment

Pressure pain threshold

Algometry kg/cm²

means
GroupnBaselineFollow-up
ESWT153.42 (SD 0.71)4.76 (SD 0.56)
Trigger-point injection153.56 (SD 1.08)3.93 (SD 0.95)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

04
One month after treatment

Pressure pain threshold

Algometry kg/cm²

means
GroupnBaselineFollow-up
ESWT153.42 (SD 0.71)4.95 (SD 0.64)
Trigger-point injection153.56 (SD 1.08)3.89 (SD 0.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Oswestry disability2 reported outcomes
05
Immediately after third treatment

Oswestry disability

ODI points

means
GroupnBaselineFollow-up
ESWT1526.47 (SD 7.4)15.67 (SD 9.43)
Trigger-point injection1531.71 (SD 8.97)20.79 (SD 10.37)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

06
One month after treatment

Oswestry disability

ODI points

means
GroupnBaselineFollow-up
ESWT1526.47 (SD 7.4)15.53 (SD 9.5)
Trigger-point injection1531.71 (SD 8.97)20.64 (SD 10.28)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

RM (source-labelled Roles and Maudsley)2 reported outcomes
07
Immediately after third treatment

RM: source instrument identity uncertain

RM (source-labelled Roles and Maudsley) reported points

means
GroupnBaselineFollow-up
ESWT1516.2 (SD 4.28)9.67 (SD 4.61)
Trigger-point injection1517.29 (SD 5)11.07 (SD 5.41)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Instrument identity is unresolved: the source labels this Roles and Maudsley, but baseline values 16–17 are incompatible with its categorical method description. These numbers are not a verified validated scale; do not relabel as Roland-Morris. Mean±SD transcribed as printed.

08
One month after treatment

RM: source instrument identity uncertain

RM (source-labelled Roles and Maudsley) reported points

means
GroupnBaselineFollow-up
ESWT1516.2 (SD 4.28)9.2 (SD 4.18)
Trigger-point injection1517.29 (SD 5)12.71 (SD 4.36)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Instrument identity is unresolved: the source labels this Roles and Maudsley, but baseline values 16–17 are incompatible with its categorical method description. These numbers are not a verified validated scale; do not relabel as Roland-Morris. Mean±SD transcribed as printed.

Quebec Back Pain Disability Scale2 reported outcomes
09
Immediately after third treatment

Quebec disability

Quebec Back Pain Disability Scale points

means
GroupnBaselineFollow-up
ESWT1548.13 (SD 19.18)24.4 (SD 12.3)
Trigger-point injection1553.57 (SD 16.44)34.43 (SD 19.1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

10
One month after treatment

Quebec disability

Quebec Back Pain Disability Scale points

means
GroupnBaselineFollow-up
ESWT1548.13 (SD 19.18)23.3 (SD 10.22)
Trigger-point injection1553.57 (SD 16.44)33.86 (SD 17.82)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Reported group means; within-group change is not a between-group treatment effect.

Analysis details and source

Mean ± SD as printed. No effect or confidence interval reconstructed.

Comparative changes1 reported outcome
11
As reported in the article

Comparative changes

Qualitative finding

At one month VAS was 2.13±0.92 with ESWT versus 3.86±0.95 with injection; pressure threshold 4.95±0.64 versus 3.89±0.90 kg/cm². Figure 1 reports comparative change p=.001 for both pain outcomes. ODI, RM and Quebec differences were not significant (p=.160,.155,.089). Pain associations favored ESWT; causal superiority is not established by patient-selected allocation.

Analysis details and source

Qualitative extraction preserves the source scope.

How treatment was delivered
ESWT

Dornier AR2, ultrasound-guided to tender QL belly, 2,000 shocks at 0.085–0.148 mJ/mm², three sessions at three-day intervals. Prone positioning and ultrasonography were used to locate the muscle.

Injection and shared care

Ultrasound-guided trigger-point injection three times at three-day intervals. Injectate and volume are not reported. Both groups received analgesics, rest and therapeutic exercise.

HARMS & TOLERABILITY

No serious adverse events such as intolerable pain or subcutaneous infection were reported in either group. This small one-month observation cannot exclude uncommon or delayed events.

LIMITS OF THE ANALYSIS

Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.
Research review

Source-linked critical reading

nonrandom comparative

Reading depthMaterial consulted
Technical source record

Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The article cites no supplementary material.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Retrospective nonrandomized comparison: patients selected treatment after explanation. Thirty hospitalized patients were divided 15/15; preference and co-interventions can confound the apparent difference.

Participants and setting

Patients hospitalized April 2015–June 2016 with isolated QL myofascial pain lasting over three months. Imaging/electrodiagnosis excluded other spinal causes. Mean ages 55.46 and 53.13 years; 17 men/13 women overall.

Treatment

Dornier AR2, ultrasound-guided to tender QL belly, 2,000 shocks at 0.085–0.148 mJ/mm², three sessions at three-day intervals. Prone positioning and ultrasonography were used to locate the muscle.

Comparison

Ultrasound-guided trigger-point injection three times at three-day intervals. Injectate and volume are not reported. Both groups received analgesics, rest and therapeutic exercise.

Outcomes and timing

Primary pain outcomes were VAS 0–10 and pressure-pain threshold. Secondary outcomes were ODI, a measure labelled RM and Quebec disability score, at baseline, immediately after treatment and one month later.

What the results show

At one month VAS was 2.13±0.92 with ESWT versus 3.86±0.95 with injection; pressure threshold 4.95±0.64 versus 3.89±0.90 kg/cm². Figure 1 reports comparative change p=.001 for both pain outcomes. ODI, RM and Quebec differences were not significant (p=.160,.155,.089). Pain associations favored ESWT; causal superiority is not established by patient-selected allocation.

Harms

No serious adverse events such as intolerable pain or subcutaneous infection were reported in either group. This small one-month observation cannot exclude uncommon or delayed events.

Limits and disclosures

Preference-based allocation, small inpatient sample, no sham and short follow-up. The RM outcome is named Roles/Maudsley, but Table 1 scores around 16–17 conflict with the categorical method description; it must not be relabelled Roland-Morris without correction. Supported by Je Won Research Foundation; no relevant conflicts declared.

Application to care

Results apply to selected inpatients with isolated QL pain receiving shared conservative care. Disability benefit over injection was not demonstrated, and longer-term outpatient outcomes remain unknown.

What remains to be tested

Randomize treatment, specify injectate and shared care, resolve RM instrument identity, blind assessors and report prespecified pain/disability contrasts with intervals and longer follow-up.

THE ORIGINAL SOURCE

Read the original article.

Extracorporeal Shock Wave Therapy Versus Trigger Point Injection in the Treatment of Myofascial Pain Syndrome in the Quadratus Lumborum

Hong JO, Park JS, Jeon DG, Yoon WH, Park JH. · Ann Rehabil Med · 2017

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →